Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1287
Full metadata record
DC FieldValueLanguage
dc.contributorUrbanic, Karen F.en_US
dc.contributorThursky, Karinen_US
dc.contributorKong, David C. M.en_US
dc.contributorJohnson, Paul D. R.en_US
dc.contributorSlavin, Monica A.en_US
dc.date.accessioned2019-02-21T03:57:00Z-
dc.date.available2019-02-21T03:57:00Z-
dc.date.issued2018-
dc.identifier.govdoc01226en_US
dc.identifier.urihttp://hdl.handle.net/11054/1287-
dc.description.abstractPurpose of review: To outline key drivers and components of antifungal stewardship (AFS) programmes, the evidence for specific interventions, and methods to assess performance of programmes. Recent findings: Recent developments in antifungal resistance and breakthrough invasive fungal diseases have increased the urgency for effective AFS. In practice, however, few hospitals have dedicated AFS programmes. To date, AFS programmes have centred around the provision of expert bedside reviews and have reduced costs and consumption of antifungal agents. Incorporating tools such as fungal diagnostics and therapeutic drug monitoring into AFS programme models is recommended. However, the application and impact of these tools in this context have not been adequately assessed. The effectiveness of AFS programmes has been measured in multiple ways but a standardized method of evaluation remains elusive. Few studies have explored the impact of AFS interventions on patient outcomes. Summary: The uptake of formal AFS programmes has been slow. New initiatives integrating AFS tools in programmes, and measuring the impacts on patient outcomes are required given such data are not readily available. A comprehensive approach to evaluate AFS programmes by correlating the quantity and quality of antifungal prescribing with impacts on patient outcomes is needed. Consensus definitions for core AFS metrics are required to benchmark performance and are essential to the resourcing and sustainability of these programmes.en_US
dc.description.provenanceSubmitted by Gemma Siemensma (gemmas@bhs.org.au) on 2019-02-06T01:43:18Z No. of bitstreams: 0en
dc.description.provenanceApproved for entry into archive by Gemma Siemensma (gemmas@bhs.org.au) on 2019-02-21T03:57:00Z (GMT) No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2019-02-21T03:57:00Z (GMT). No. of bitstreams: 0 Previous issue date: 2018en
dc.relation.uri10.1097/QCO.0000000000000497en_US
dc.titleAntifungal stewardship: developments in the field.en_US
dc.typeJournal Articleen_US
dc.type.specifiedArticleen_US
dc.bibliographicCitation.titleCurrent Opinion in Infectious Diseases.en_US
dc.bibliographicCitation.volume31en_US
dc.bibliographicCitation.issue6en_US
dc.bibliographicCitation.stpage490en_US
dc.bibliographicCitation.endpage498en_US
dc.subject.healththesaurusANTIFUNGAL AGENTSen_US
dc.subject.healththesaurusANTIFUNGAL STEWARDSHIPen_US
dc.subject.healththesaurusINVASIVE FUNGAL DISEASESen_US
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.